Hixon Zuercher LLC Acquires 226 Shares of Edwards Lifesciences Corporation $EW

Hixon Zuercher LLC grew its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 0.7% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 30,731 shares of the medical research company’s stock after buying an additional 226 shares during the quarter. Hixon Zuercher LLC’s holdings in Edwards Lifesciences were worth $2,403,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Quantbot Technologies LP acquired a new position in Edwards Lifesciences in the first quarter worth about $26,000. SouthState Corp bought a new stake in shares of Edwards Lifesciences in the 1st quarter valued at approximately $27,000. Rosenberg Matthew Hamilton bought a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $28,000. Tradewinds Capital Management LLC raised its holdings in shares of Edwards Lifesciences by 102.5% in the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company’s stock worth $29,000 after buying an additional 205 shares in the last quarter. Finally, Rossby Financial LCC bought a new position in shares of Edwards Lifesciences during the 1st quarter worth approximately $29,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $76.15 on Friday. Edwards Lifesciences Corporation has a 1 year low of $64.89 and a 1 year high of $83.00. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The firm’s 50 day moving average is $77.37 and its 200-day moving average is $76.43. The firm has a market capitalization of $44.70 billion, a price-to-earnings ratio of 10.96, a PEG ratio of 3.65 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.70 EPS. Sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

EW has been the topic of a number of analyst reports. Argus upgraded Edwards Lifesciences to a “strong-buy” rating in a research note on Thursday, July 10th. Wall Street Zen lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a report on Monday, September 29th. JPMorgan Chase & Co. lifted their price target on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the company a “neutral” rating in a report on Friday, July 25th. Canaccord Genuity Group boosted their price target on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company a “hold” rating in a research report on Friday, July 25th. Finally, William Blair raised shares of Edwards Lifesciences to a “strong-buy” rating in a report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average price target of $87.06.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.